Clinical Trial Update: Low-dose Nilotinib and Imatinib Combination in Chronic Myeloid Leukemia Patients, With Failure, Suboptimal Response or Treatment Intolerance [Phase 3]

View source ↗

Summary

Phase 3 trial assessing a low-dose combination of nilotinib and imatinib in chronic myeloid leukemia patients with treatment failure, suboptimal response, or in…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• Gleevec (Imatinib)
• Tasigna (nilotinib)

Snippet

Sponsor: Hospital Universitario Dr. Jose E. Gonzalez | Conditions: Leukemia, Myeloid, Chronic, BCR-ABL Positive | Phase 3 | Status: COMPLETED